Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.

Wang W, Wei R, Huang Z, Luo J, Pan Q, Guo L

Diabetes/metabolism research and reviews25 Jun 2023Cited by 16 (Europe PMC)

PMID37356073DOI10.1002/dmrr.3680PepBankPUB-37356073

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes and overweight or obesity, pooled GLP-1RAs (liraglutide among them) led to more regression to normoglycemia than placebo (OR 4.56).
In plain wordsIn adults with prediabetes and overweight, GLP-1 drugs as a group helped more people return to normal blood sugar than placebo.
Peptide
Liraglutide
Outcome
IncreaseRegression from prediabetes to normoglycemia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Odds ratio, regression to normoglycemia
4.56 NA
GLP-1RAs vs placebo
Source sentences
Summary
More individuals in GLP-1RAs group regressed from prediabetes to normoglycemia than individuals in the placebo group (OR = 4.56, 95% CI:3.58, 5.80, P = 0.004
2 context sentences(design, population, supporting numbers)
Summary · context
A search of PubMed, Embase, Cochrane Library, and Web of Science databases was performed to identify randomised controlled trials (up to 4 July 2022) which evaluated the effect of GLP-1RA on prediabetes with overweight/obesity.
Summary · context
Eight hundred and nine articles were retrieved (80 from PubMed, 481 from Embase, 137 from Cochrane library, and 111 from Web of Science) and a total of 5 articles were included in this meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3735607301
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes and overweight or obesity, pooled GLP-1RAs (liraglutide among them) led to fewer diabetes diagnoses than placebo (OR 0.31).
In plain wordsIn adults with prediabetes and overweight, GLP-1 drugs as a group led to fewer diabetes diagnoses than placebo.
Peptide
Liraglutide
Outcome
DecreaseDiagnosis of diabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Odds ratio, diabetes diagnosis
0.31 NA
GLP-1RAs vs placebo
Source sentences
Summary
fewer individuals in GLP-1RAs group were diagnosed with diabetes than those in the placebo group (OR = 0.31, 95% CI:0.12,0.81, P = 0.017
2 context sentences(design, population, supporting numbers)
Summary · context
A search of PubMed, Embase, Cochrane Library, and Web of Science databases was performed to identify randomised controlled trials (up to 4 July 2022) which evaluated the effect of GLP-1RA on prediabetes with overweight/obesity.
Summary · context
Eight hundred and nine articles were retrieved (80 from PubMed, 481 from Embase, 137 from Cochrane library, and 111 from Web of Science) and a total of 5 articles were included in this meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3735607302
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with prediabetes and overweight or obesity, pooled GLP-1RAs (liraglutide among them) reduced fasting glucose (mean difference -0.41 mmol/L).
In plain wordsIn adults with prediabetes and overweight, GLP-1 drugs as a group lowered fasting blood sugar.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference, fasting glucose
−0.41 mmol/L
GLP-1RAs vs placebo
Source sentences
Summary
Results from five studies showed that GLP-1RAs significantly reduced fasting glucose (mean difference = -0.41 mmol/L, 95% CI: -0.58, -0.25, P 2 = 42%).
2 context sentences(design, population, supporting numbers)
Summary · context
A search of PubMed, Embase, Cochrane Library, and Web of Science databases was performed to identify randomised controlled trials (up to 4 July 2022) which evaluated the effect of GLP-1RA on prediabetes with overweight/obesity.
Summary · context
Eight hundred and nine articles were retrieved (80 from PubMed, 481 from Embase, 137 from Cochrane library, and 111 from Web of Science) and a total of 5 articles were included in this meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3735607303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.